BioDirection Inc.
Point-of-care blood test for traumatic brain injury
This article was originally published in Start Up
Executive Summary
BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injuries. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.
You may also be interested in...
Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Start-Up Spotlight: Tyto Care Brings Medical Exams To Homes
Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.
Market Intel: 3D Bioprinting Forges Ahead With Mini Human Heart, Human Tissue
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.